Navigation Links
Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
Date:4/14/2009

PHILADELPHIA Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

Pancreatic cancer is one of the deadliest cancers, and less than 4 percent of the 200,000 patients diagnosed annually live more than five years. The only available clinical treatment is gemcitabine, but this has yet to show a survival benefit.

Scientists are testing a variety of experimental therapies to bring pancreatic cancer under control. At Amgen, Pedro J. Beltran, Ph.D., a principal scientist in oncology research, is experimenting with AMG 479, a fully human anti-IGF-1 monoclonal antibody.

"We know that insulin-like growth factors play a role in cancer development, particularly in mediating cell survival. This is the first drug that specifically targets the receptor for these growth factors without cross-reacting with the closely related insulin receptor," said Beltran.

In the in vitro study, AMG 479 bound to IGF-1R and blocked both IGF-1 and IGF-2 binding factors 1 and 2. It also completely inhibited ligand-induced activation in some growth factors, which led to a decreased cellular viability. When Beltram and colleagues measured the effect of AMG 479 on pancreatic cancer cells in vivo, the inhibition rate was approximately 80 percent inhibition of tumor growth and receptor expression was observed.

"These data clearly show that AMG 479 is a clinical candidate for pancreatic cancer therapy, either alone or in combination with gemcitabine," he said.

Beltran said researchers are currently testing AMG 479 in nine separate phase II studies of various cancer types; he expects the effect will be seen beyond pancreatic cancer.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

0

GOOD

Page: 1

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Following the recent outbreak of fake Amazon emails ... team at idcloak Technologies has identified a new form ... web-born malware. Gill-Chris Welles of the idcloak security ... privacy and security than traditional antivirus software. ... AV software cannot be depended on: it takes a ...
(Date:5/23/2013)... 2013 When Teachers Notebook reached out ... raise funds for the Moore, OK tornado victims, they ... items that could be sold for around $10.00 with ... at Teachers Notebook were overwhelmed by the response from ... of materials within the first 12 hours of the ...
(Date:5/23/2013)... GBI Research’s analysis indicates that the global critical care ... of players accounting for a major proportion of the overall ... between 2006 and 2012, possibly due to the lack of ... in the US. , GBI Research estimates that the ... 2012, having grown in size at a CAGR of 11% ...
(Date:5/22/2013)... The surging growth in specialty beds ... marketing claims to compare mattresses often proves a bit ... bed blog , offers shoppers faced with this dilemma ... latest article. , Titled “ Mattress Comparison Overview – ... readers through the basics of innerspring beds as well ...
(Date:5/22/2013)... On May 16, 2012, LifeHealthPro reported ... funeral concierge can help families negotiate lower costs for all ... Financials announces their top 3 reasons to hire a ... the U.S. having dropped 7.3 percent from $55,438 to $51,404 ... costs 12.6% of an average U.S. households annual income. , ...
Breaking Medicine News(10 mins):Health News:Effective virus protection without anti-virus software, identifies idcloak 2Health News:Teachers Rally to Raise Funds for Moore Tornado Victims 2Health News:MarketResearch.com Report – Increased Cost of Albumin was Main Factor for Double-Digit Growth of Global Critical Care Market Between 2006 and 2012 2Health News:Mattress Comparison Overview Released by The Sleepy Shopper; Compares Top Types and Brands 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 3
... Stanford University School of Medicine,s Todd Ferris, Associate ... Information Privacy and Security; and Robert ... WHAT: "Improving Network Security and Management", WHEN: 11:45 ... Western Regional Conference 2008 InterContinental ...
... in a cup, instead of bracing for a needle prick, ... major step in that direction is the cataloguing of the ... saliva, identified by a consortium of three research teams, according ... Research. Replacing blood draws with saliva tests promises to make ...
... 25 Laerdal Medical,Corporation announces a strategic ... Supply Chain Systems has awarded Laerdal,a multi-year ... The,contract is effective January 1 through December ... ), Bruce Cadwell, Laerdal,s National Accounts ...
... Fit and Fabulous ... to Lower Breast Cancer Risk, DALLAS, March 25 ... Cure(R),s Circle of Promise campaign has,teamed with Dr. Rovenia ("Dr. Ro") ... living to,help lower their risk of breast cancer. In the coming ...
... Skin Cancer with State-of-the-Art Technology, EAST RUTHERFORD, ... one of the nation,s top 10 public relations ... client roster. Developed in New,Zealand, MoleSafe is a ... of moles and other suspicious lesions to,help detect ...
... 25 Ochsner Health System of New,Orleans ... throughout their,perioperative (surgical) process with technology from ... (AIMS), medication,management system and presurgical care management ... implementation of DocuSys, Ochsner will,strategically focus on ...
Cached Medicine News:Health News:Stanford University School of Medicine to Address 'Improving Network Security and Management' at EDUCAUSE Western Regional Conference 2008 Using Lancope's StealthWatch System for Network Behavior Analysis 2Health News:Spit tests may soon replace many blood tests 2Health News:Spit tests may soon replace many blood tests 3Health News:Laerdal Medical Announces Strategic Relationship 2Health News:Dr. Rovenia Brock Brings Secrets of Living Healthy to Susan G. Komen for the Cure(R)'s Circle of Promise 2Health News:Dr. Rovenia Brock Brings Secrets of Living Healthy to Susan G. Komen for the Cure(R)'s Circle of Promise 3Health News:MWW Group Retained by MoleSafe 2Health News:Ochsner Health System Partners with DocuSys for Presurgical Care, AIMS and Medication Management Technology 2Health News:Ochsner Health System Partners with DocuSys for Presurgical Care, AIMS and Medication Management Technology 3
(Date:5/22/2013)... 22, 2013 Attorney Advertising -- Bronstein, Gewirtz ... behalf of purchasers of the securities of AMAG ... -News).  The investigation focuses on whether the Company ... On May 22, 2013, Shares of AMAG ... the company announced in regulatory filing that it ...
(Date:5/22/2013)... and MUNICH , May 22, 2013 /PRNewswire/ ... marketer of transcatheter aortic valve implantation (TAVI) systems for the ... results of the J enaValve Eval U ation of ... Pa T ients with S E vere Ao R tic ... . JUPITER is a post-market registry to evaluate five-year long ...
(Date:5/22/2013)... 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine. The U.S. Food ... 2010 after a series of trials. These trials found ... pneumococcal types than the previously used PCV7, did not ...
Breaking Medicine Technology:Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4
... for New Combination, PARSIPPANY, N.J., May 21, ... amlodipine besylate with the angiotensin,receptor blocker olmesartan ... and diastolic blood pressure in,patients with hypertension, ... of Hypertension's Twenty-Second Annual Scientific,Meeting and Exposition ...
... Company (NYSE: BMY) today announced new data ... Baraclude (entecavir),demonstrated greater viral load reduction than ... was also seen at weeks 12 (primary ... randomized viral kinetics study,of 69 antiviral-naive chronic ...
Cached Medicine Technology:Amlodipine and Olmesartan Study Results Released; Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 2Amlodipine and Olmesartan Study Results Released; Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: